Tiquizium bromide is an orally active, atropine-type, nonselective muscarinic antagonist and novel spasmolytic agent. Tiquizium bromide inhibits the developments of gastric lesions and duodenal lesions. Tiquizium bromide induces the mydoriasis and inhibits the Pilocarpine ( HY-B0726A )-induced salivation.
Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Peptic Ulcer Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > mAChR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.